替吉奥同步放化疗治疗晚期食管癌效果分析  

The effect analysis of S-1 and concurrent chemoradiotherapy in the treatment of advanced esophageal cancer

作　　者：兰守丽 

机构地区：[1]平顶山煤业集团总医院肿瘤科,河南平顶山467000

出　　处：《中国医学前沿杂志（电子版）》2014年第8期121-123,共3页Chinese Journal of the Frontiers of Medical Science(Electronic Version)

摘　　要：目的探讨替吉奥在晚期复发性食管癌治疗中的临床疗效和不良反应。方法将80例晚期复发性食管癌患者采用数字随机法分为治疗组和对照组,每组各40例。首先对两组患者进行放疗,随后治疗组患者采用替吉奥方案治疗,第1天和第8天静脉滴注替吉奥1000 mg/m2＋生理盐水100 ml,滴注6小时。对照组患者采用氟尿嘧啶联合奈达铂治疗,第1~5天每日静脉滴注20-30 mg/kg氟尿嘧啶,第1-3天每日静脉滴注奈达铂25 mg/m2。一周期为21天,所有患者至少完成3个周期的治疗。结果治疗组患者完全缓解6例,部分缓解25例,稳定5例,进展4例,总有效率为77.5%;对照组患者完全缓解4例,部分缓解21例,稳定9例,进展6例,总有效率为62.5%。常见不良反应为中性粒细胞减少、血小板减少和血红蛋白减少,呕吐、肝肾损坏症状较轻,对照组患者恶心呕吐发生率明显高于治疗组（P〈0.05）,治疗组患者血小板减少发生率高于对照组（P〈0.05）。结论替吉奥治疗复发性食管癌疗效较好,不良反应较轻,适合临床推广应用。Objective To explore the effect of S-1 and concurrent chemoradiotherapy in the treatment of advanced esophageal cancer. Method 80 cases of patients with advanced recurrent esophageal cancer were randomly divided into treatment group and control group, 40 cases in each group. First of two groups of patients with radiation therapy, then for S-1 treatment, they were treated by 1 and 8 days intravenous drip for S-1 1000 mg/m2 and physiological saline 100 ml, drip 6 hours. The control group were treated by combined therapy with nedaplatin and fluorouracil, 1 - 5 days intravenous drip 20 - 30 mg/kg fluorouracil, 1-3 days intravenous drip nedaplatin 25 mg/m2. A cycle for 21 days, all patients completed at least three cycles of treatment. Result 6 cases of treatment group patients with complete remission, partial remission in 25 cases, stable in 5 cases, and 4 cases of progress. The total effective rate was 77.5%; control group patients with complete remission in 4 cases, partial in 21 cases, 9 cases of stability and progress in 6 cases. The total effective rate was 62.5%. The common adverse reactions as neutropenia, thrombocytopenia and hemoglobin decreased. Vomiting, liver and kidney damage symptoms lighter, incidence of nausea and vomiting was significantly higher in control group patients in treatment group （P 〈 0.05）, treatment group patients with thrombocytopenia was higher than control group （P 〈 0.05）. Conclusion S-1 treatment for recurrent esophageal cancer curative effect is good, adverse reaction is lighter, and suitable for clinical application.

关 键 词：替吉奥 同步放化疗 晚期复发性食管癌 

分 类 号：R735.1[医药卫生—肿瘤]